Idorsia

IDIA.SWApproved

Allschwil, SwitzerlandFounded 2017idorsia.com

Idorsia is a public Swiss biotech company that emerged from the demerger of Actelion following its acquisition by Johnson & Johnson in 2017. It has built a balanced portfolio with one commercial product (QUVIVIQ for insomnia) and several late-stage clinical assets, including TRYVIO/JERAYGO for resistant hypertension. The company's strategy focuses on unlocking the value of its commercial product, expanding strategic partnerships, advancing its differentiated pipeline, and maintaining financial discipline.

Market Cap

$1.0B

Founded

2017

Employees

~500

Focus

Small Molecules

IDIA.SW · Stock Price

USD 3.1514.55 (-82.20%)

Historical price data

AI Company Overview

Technology Platform

Specialized small-molecule drug discovery engine and a glycoconjugate vaccine platform utilizing synthetic antigenic glycan molecules.

Pipeline Snapshot

105

105 drugs in pipeline, 14 in Phase 3

Drug	Indication	Stage
Daridorexant 50 mg + Placebo	Alzheimer Disease	Approved
Daridorexant + Placebo	Insomnia Disorder	Approved
Daridorexant 25 mg + Daridorexant 50 mg	Insomnia Disorder	Phase 3
Daridorexant 10 mg + Daridorexant 25 mg + Daridorexant 50 mg + Placebo	Insomnia Disorder	Phase 3
Clazosentan + Placebo	Aneurysmal Subarachnoid Hemorrhage	Phase 3

FDA Approved Drugs

TRYVIONDAMar 19, 2024

QUVIVIQNDAJan 7, 2022

Opportunities

Significant growth opportunity from the global expansion of QUVIVIQ in the large insomnia market.

Near-term pipeline catalysts in 2026 from Phase 3 readouts for cenerimod and selatogrel could create substantial value.

The company's partnership model provides non-dilutive funding and de-risks development while retaining economic interest.

Risk Factors

Heavy reliance on the commercial success of QUVIVIQ.

Clinical failure of late-stage assets (cenerimod, selatogrel) would be a major setback.

The company is not yet profitable from operations and faces ongoing financial sustainability challenges.

Leadership transition with the search for a permanent CEO adds uncertainty.

Competitive Landscape

Competes in insomnia with other orexin antagonists (Belsomra, Dayvigo) and generics. TRYVIO is first-in-class for resistant hypertension but competes with entrenched drug classes. Pipeline assets face competition in crowded markets (SLE biologics, AMI antiplatelets). Idorsia's differentiation lies in its specialized discovery engine targeting novel mechanisms and its strategic use of partnerships.

Publications

Patents

Pipeline

105

FDA Approvals